Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: People on the Move

Edward D. Kobus, President of Invado Pharmaceuticals, Joins Transdermal Delivery Solutions Corp. (TD

Thursday, September 29, 2016   (0 Comments)
Share |

Edward D. Kobus, President of Invado Pharmaceuticals, Joins Transdermal Delivery Solutions Corp. (TDSC) Board of Advisors

TDSC, a leader in the development of breakthrough spray-on drug delivery systems, announced today key advisor and veteran pharma entrepreneur to accelerate progress

PALM BEACH GARDENS, Fla.--()--Transdermal Delivery Solutions Corporation (TDSC) announced today that Edward “Ed” D. Kobus, testosterone hormone replacement therapies veteran, has joined its Board of Advisors.

"We are very pleased to have Ed Kobus, a veteran professional and pharma entrepreneur, join our Board of Advisors,” said Kenneth Kirby, President of TDSC. “His years of experience with AndroGel® & Testim®, his knowledge of Medicare and managed care reimbursement as well as his reputation, relationships and track-record of success, validating his record of billions in revenue from transdermal testosterone, will be an invaluable asset to our organization moving forward as we commercialize the Testagen® opportunity.”

Kobus was involved in the initial development of AndroGel with Unimed Pharmaceuticals. Subsequently, he launched AndroGel as both a Regional Sales Director and Area Business Manager in Managed Care for Solvay Pharmaceuticals, after the acquisition of Unimed by Solvay. He successfully negotiated a $75 million sale, the largest contract in Solvay USA history. AndroGel’s sales under AbbVie currently exceed $1.4 Billion per year. Subsequently, he was hired by Solvay’s lead competitor Auxilium, and as Director of National Accounts, he launched Testim, Auxilium’s Testosterone Gel competitor and he collaborated on developing and implementing their national Medicare Part D contract strategy and secured 24 major formulary listings for Testim in an 18-month period. Testim’s sales now exceed $400 million per year. Kobus subsequently formed Invado Pharmaceuticals, developed and launched a product, obtained substantial Medicare reimbursement and managed care listings and successfully vended the product to Valeant Pharmaceuticals of Canada in 2015.

Kobus has 25+ years of experience in the pharmaceutical industry focusing on transdermal drug delivery, medical devices (implant) and alternative therapies. He has demonstrated success in start-up and turnaround environments, and is an acknowledged expert at accomplishing reimbursement with Medicare Part B, CMS, PBMs, and all third party payers. He is an entrepreneurial pharmaceutical director with proven success in Managed Markets, Sales, Sales Management, Managed Care Marketing and Contracting.

“I am excited to join Ken and the TDSC team and look forward to resuming pioneering in male hormone replacement with TDSC’s paradigm-shifting platform technology,” said Edward Kobus. “The main challenge limiting exponential growth for the testosterone products has been the lifestyle limitations and access to safer products. The Testagen® fast-drying product solves all of these issues and will be attractive to prescribers, patients and their families. Consequently, potential partners or the company itself will be well-positioned to acquire a big share of a market with substantial growth potential.”

About Low Testosterone

Low Testosterone or ‘Low T,’ also known as hypogonadism, is a condition in men characterized by the body’s failure to produce normal amounts of the hormone testosterone, a male sex hormone produced by the testes. Low T affects nearly 14 million men in the United States; yet only 9 percent (1.3 million) of men diagnosed with Low T are receiving treatment for the condition. Symptoms associated with Low T include erectile dysfunction and decreased sexual desire, fatigue, loss of energy, mood depression, regression of secondary sexual characteristics and osteoporosis.

About Transdermal Delivery Solutions (TDSC)

TDSC is committed to advancing the science of transdermal drug delivery using its patented spray-on delivery system platform, HypoSpray®. TDSC’s proprietary system enables a much larger number of medications to be delivered directly through the skin, for systemic or localized application, utilizing its rapid acting, patchless, spray-on technology. TDSC’s technology represents a paradigm-shift in drug delivery.


About Hormone Replacement Technologies (HRT, Inc.)

HRT, Inc. is a subsidiary of TDSC that focuses on creating innovative, specific and medically current solutions impacting hormone replacement needs.

Company: Hormone Replacement Technologies, Inc.:


MarCom Consultant (for TDSC)
Cindy Metzler, 561-429-6429

BioFlorida, Inc. | 901 NW 35th Street | Boca Raton, FL 33431
(P) 561-653-3839 (F) 561-653-3840
Membership Management Software Powered by®  ::  Legal